Next 10 |
Harpoon Therapeutics is a platform immunotherapy company using its TriTAC technology to develop more stable bispecifics to treat cancer. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform. Ultimately, Harpoon ...
Merger activity increased last week. Six multi-billion-dollar deals announced. SPAC frenzy hits a new record. For further details see: Merger Arbitrage Mondays: SPAC IPOs Set A New Record
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major averages finished the week with sharp losses, despite a Friday rebound in the big tech stocks following an earlier selloff sparked ...
Best Biotech Stocks To Buy [Or Sell] Right Now Investors looking for high returns could turn to biotech stocks . These stocks are more volatile than your usual pick. However, could this be the right time to buy biotech stocks after rising Treasury yields continue to spark a tech...
Merck (NYSE: MRK) and Pandion Therapeutics, Inc. (NASDAQ: PAND) have reported entry into a definitive agreement where Merck will acquire Pandion for USD 60 per share in cash or a total equity value of USD 1.85 Billion. “This acquisition builds upon Merck...
Gainers: Pandion Therapeutics (PAND) +133%.GameStop (GME) +66%.ChromaDex (CDXC) +59%.Dynatronics (DYNT) +57%.Koss (KOSS) +54%.Stereotaxis (STXS) +33%.ASLAN Pharmaceuticals (ASLN) +29%.Socket Mobile (SCKT) +26%.AeroCentury (ACY) +24%.Brookdale Senior Living (BKD) +21%.Loser...
Gainers: Pandion Therapeutics (PAND) +132%, Dynatronics (DYNT) +68%, ChromaDex (CDXC) +30%, ASLAN Pharmaceuticals (ASLN) +28%, Brookdale Senior Living (BKD) +22%.Losers: U.S. Physical Therapy (USPH) -21%, CollPlant Biotechnologies (CLGN)&...
Pandion Therapeutics (PAND) +132% as Merck to acquire the company for $2.0B.Koss Corporation (KOSS) +92%.Dynatronics Corporation (DYNT) +91% on extension of key distribution agreement.GameStop Corp. (GME) +72%.AmeriServ Financial (ASRV) +33%.Socket Mobile (SCKT) +31% on Q4 resu...
Merck (MRK) has agreed to acquire Pandion Therapeutics (PAND) for $60 per share in an all-cash deal valuing Pandion at $1.85B.Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Pandion, and subsequently Merck’...
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreem...
News, Short Squeeze, Breakout and More Instantly...
Pandion Therapeutics Inc. Company Name:
PAND Stock Symbol:
NASDAQ Market:
Best Biotech Stocks To Buy [Or Sell] Right Now Investors looking for high returns could turn to biotech stocks . These stocks are more volatile than your usual pick. However, could this be the right time to buy biotech stocks after rising Treasury yields continue to spark a tech...
Merck (NYSE: MRK) and Pandion Therapeutics, Inc. (NASDAQ: PAND) have reported entry into a definitive agreement where Merck will acquire Pandion for USD 60 per share in cash or a total equity value of USD 1.85 Billion. “This acquisition builds upon Merck...
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreem...